Outsourcing global clinical

& medical engagement for accelerated drug approval

& acceptance
Flexible, scalable sales teams for rapid product launch

& lifecycle management
Real-time patient-level insights powered by a
one-of-a-kind comprehensive
qualitative database + platform — AnswerY™

Premium content & audience access to critical oncology care networks

Continuous growth for teams and individuals led by pharma industry experts

Burden Of Alzheimer’s Disease On Patients & Caregivers

Picture of

PUBLISHED

May 6, 2024
Elderly woman with female caregiver at home

Clinical and Humanistic Burden Associated With Alzheimer’s Disease In The United States: 
An Analysis Of Patient Characteristics, Treatment Patterns, And Quality Of Life Using A Physician Notes Real-World Database 

This poster was originally presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference 2024, held May 5June 8, 2024, in Atlanta, GA. 

Authors: David Iwanyckyj, Pablo Racana, Ashley Gamble, PhD, Melanie Jardim, PhD 

Affiliations: Amplity, Langhorne, PA, USA 


Introduction 
 

This study leveraged AnswerY™ (formerly known as Amplity Insights), our robust, HIPAA-compliant real-world database (RWD), composed of transcribed physician notes, to characterize the real-world clinical and humanistic burden of Alzheimer’s disease (AD).  


Methods 
 

  • >60 million electronic medical transcription records from the AnswerY RWD were analyzed from nearly 120,000 healthcare providers at ~40,000 inpatient/outpatient care sites across 50 states and 2 U.S. territories 
  • Patient-level characteristics, comorbidities, symptoms, quality of life (QoL), testing, and treatment usage were summarized and described for the following 4 cohorts: All patients, patients aged 50-64 years, patients aged 65-79 years, and patients aged ≥80 years 


Results
 

  • The path to AD diagnosis can be long, and patients with AD experience psychological symptoms years in advance of diagnosis and continue to experience those symptoms at higher rates post-diagnosis than cognitive impairment and confusion symptoms 

 

Alzheimer’s disease patients experience psychological symptoms years in advance of diagnosis.

  • Disease symptoms significantly impact patients and carry a significant QoL burden, which extends to their caregivers 

 

Disease symptoms impact patients and carry a significant quality of life burden.

  • Diagnostic and treatment decisions remain focused on clinical symptoms versus a biomarker-guided approach 


Conclusions
 

  • Analysis of this RWD revealed the pattern of symptoms and comorbidities experienced by patients with AD, which impacts QoL and creates a burden that extends to their caregivers  
  • Use of these data can help identify barriers to patients accessing biomarker evaluation in AD and opportunities to improve the quality of care in different patient populations


DOWNLOAD POSTER 

PUBLISHED •

May 6, 2024

Read Next

Young female caregiver or daughter feeding senior woman or mothe
Read Article arrow